11:00 AM - 12:30 PM

Welcome (ID 1851)

Tumor location is a key decision factor for 1st-line mCRC treatment (ID 1852)

Choosing the best 1st-line treatment for RAS wt mCRC patients (ID 1853)

Cetuximab rechallenge in 3rd line mCRC can provide a new standard of care (ID 1854)

Panel discussion: Asian hot topics (ID 1855)

Conclusions (ID 1856)